Thermo Scientific TSQ Plus Triple Quadrupole MS Portfolio

Designed to increase workflow throughput through superior data acquisition and polarity switching speeds.

By: Kristin Brooks

Managing Editor, Contract Pharma

The Thermo Scientific TSQ Plus triple quadrupole mass spectrometer (MS) portfolio is designed to increase workflow throughput through superior data acquisition and polarity switching speeds. The improved low-mass product ion transmission efficiency enhances sensitivity for key target applications. The new portfolio, which consists of the TSQ Altis Plus, TSQ Quantis Plus and TSQ Fortis Plus MS, can be used across a range of applications, from targeted quantitation to cutting-edge research. Intuitive mass calibration routines and method optimization, in combination with chromatography and data processing software solutions, aims to offer improved ease of use to address future analytical challenges.

“Laboratories performing routine quantitative experiments continue to need to identify new compounds of interest across industries, such as pharma, food and environmental, resulting in rapidly changing regulations and lower detection limits,” said August Specht, vice president, research and development, chromatography and mass spectrometry, Thermo Fisher. “In order to protect consumer and environmental health, laboratories need to provide comprehensive workflows to address evolving requirements, and the TSQ Plus triple quadrupole MS portfolio has been designed to deliver.”

The TSQ Plus triple quadrupole MS portfolio features:

Increased system uptime due to enhanced quadrupole mass stability.
Direct instrument method transfers from the existing Thermo Scientific TSQ MS portfolio to the TSQ Plus MS portfolio, enabling simplified transfers.
Integration with mzCloud database to provide Selective Reaction Monitoring (SRM) transition information with predicted collision energy.
Integration with liquid- and ion-chromatography systems and software, delivering quantitative application solutions.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters